Minimal Residual Disease (MRD)

The ability to measure minimal residual disease (MRD), which is the number of multiple myeloma (MM) cells remaining after treatment, is important for prognosis. Being able to determine how many MM cells are present will ultimately allow your oncologist to determine how well a treatment is working. Performing these tests over time can show how long the effects of treatment will last. Incredibly sensitive techniques to detect MM cells have been developed, and recent data have shown that patients who achieve a deep response to therapy with no detectable MRD (MRD-negative status) have greater survival rates.

Researchers MRDFor Researchers

Information and resources for researchers, clinicians and medical professionals.

View Now

Patients MRDFor Patients

Information and resources for multiple myeloma patients and caregivers.

View Now